CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 100 enrolled
Drug / intervention
Glecaprevir/Pibrentasvirdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03219216
NCT03219216Phase 3Completed
CompareCT.gov

A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naïve Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection

AbbVie·interventional·Posted Jul 17, 2017·Updated Mar 17, 2020

In Brief

A Phase 3 clinical trial evaluating Glecaprevir/Pibrentasvir for Hepatitis C Virus (HCV). Completed, enrolled 100 participants across 14 sites.

Detailed Summary

This was a Phase 3, open-label, multicenter study to evaluate the efficacy and safety of glecaprevir (GLE)/pibrentasvir (PIB) for an 8 or 12-week treatment duration in adults in Brazil with chronic hepatitis C virus (HCV) genotype (GT) 1 to GT6 infection, without cirrhosis or with compensated cirrhosis, who were HCV treatment-naïve.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C Virus (HCV)
CountriesBrazil
Collaborators--

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedJul 17, 2017
Enrollment StartJun 6, 2018
Primary CompletionMar 11, 2019
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 9.0 years ago

Interventions

Glecaprevir/Pibrentasvirdrug

Film-coated tablet